Molecule

A randomized, double-blind, placebo-controlled trial published in Nature reports that safiglipron, an oral small-molecule GLP-1 receptor agonist, was tested in people with early type 2 diabetes. The pill-based alternative to injectable GLP-1 drugs is drawing attention as a potentially easier-to-take option for blood sugar control and weight management.